1/14
08:21 pm
abcl
AbCellera Biologics Pivots to Internal Pipeline at JPMorgan, Teases Key Milestones for 2026 [Yahoo! Finance]
Medium
Report
AbCellera Biologics Pivots to Internal Pipeline at JPMorgan, Teases Key Milestones for 2026 [Yahoo! Finance]
1/12
09:26 am
abcl
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause [Yahoo! Finance]
Low
Report
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause [Yahoo! Finance]
1/12
09:00 am
abcl
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
Low
Report
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
1/12
01:05 am
abcl
AbCellera Biologics (NASDAQ:ABCL) was upgraded by analysts at
Wall Stree
Low
Report
AbCellera Biologics (NASDAQ:ABCL) was upgraded by analysts at
Wall Stree
1/4
01:06 am
abcl
AbCellera Biologics (NASDAQ:ABCL) was downgraded by analysts at
Wall Str
Low
Report
AbCellera Biologics (NASDAQ:ABCL) was downgraded by analysts at
Wall Str
12/27
01:05 am
abcl
AbCellera Biologics (NASDAQ:ABCL) was upgraded by analysts at
Wall Stree
Medium
Report
AbCellera Biologics (NASDAQ:ABCL) was upgraded by analysts at
Wall Stree
12/25
07:00 pm
abcl
We're Not Worried About AbCellera Biologics' (NASDAQ:ABCL) Cash Burn [Yahoo! Finance]
Medium
Report
We're Not Worried About AbCellera Biologics' (NASDAQ:ABCL) Cash Burn [Yahoo! Finance]
12/18
09:00 am
abcl
AbCellera and Bruker Reach Global Settlement of Patent Litigation
Low
Report
AbCellera and Bruker Reach Global Settlement of Patent Litigation
12/8
04:05 pm
abcl
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Low
Report
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
12/4
10:20 pm
abcl
AbCellera Biologics Inc (ABCL) Down 23% Since Q3 2025 Results [Yahoo! Finance]
Medium
Report
AbCellera Biologics Inc (ABCL) Down 23% Since Q3 2025 Results [Yahoo! Finance]
11/26
04:31 pm
abcl
AbCellera Biologics Inc. (ABCL) is a Buy at Stifel Nicolaus despite Wider Q3 Net Loss [Yahoo! Finance]
Low
Report
AbCellera Biologics Inc. (ABCL) is a Buy at Stifel Nicolaus despite Wider Q3 Net Loss [Yahoo! Finance]
11/18
06:32 am
abcl
Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution? [Yahoo! Finance]
Low
Report
Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution? [Yahoo! Finance]
11/10
10:57 am
abcl
The Best Canadian Stock You've Never Heard of [Yahoo! Finance Canada]
Low
Report
The Best Canadian Stock You've Never Heard of [Yahoo! Finance Canada]
11/10
09:00 am
abcl
AbCellera Appoints Dr. Stephen Quake to its Board of Directors
Medium
Report
AbCellera Appoints Dr. Stephen Quake to its Board of Directors
11/9
05:03 am
abcl
Assessing AbCellera Biologics (ABCL) Valuation Following Phase 1 Trial Progress and Clinical Milestones [Yahoo! Finance]
Medium
Report
Assessing AbCellera Biologics (ABCL) Valuation Following Phase 1 Trial Progress and Clinical Milestones [Yahoo! Finance]
11/8
01:18 pm
abcl
AbCellera Biologics (NASDAQ:ABCL) was downgraded by analysts at
Wall Str
Medium
Report
AbCellera Biologics (NASDAQ:ABCL) was downgraded by analysts at
Wall Str
11/8
06:57 am
abcl
AbCellera Biologics (NASDAQ:ABCL) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Medium
Report
AbCellera Biologics (NASDAQ:ABCL) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
11/7
08:07 am
abcl
AbCellera Biologics (NASDAQ:ABCL) had its "market perform" rating reaffirmed by analysts at Leerink Partners. They now have a $4.00 price target on the stock.
Medium
Report
AbCellera Biologics (NASDAQ:ABCL) had its "market perform" rating reaffirmed by analysts at Leerink Partners. They now have a $4.00 price target on the stock.
11/6
04:16 pm
abcl
AbCellera Biologics GAAP EPS of -$0.19 misses by $0.02, revenue of $8.96M beats by $2.63M [Seeking Alpha]
Low
Report
AbCellera Biologics GAAP EPS of -$0.19 misses by $0.02, revenue of $8.96M beats by $2.63M [Seeking Alpha]
11/6
04:05 pm
abcl
AbCellera Reports Q3 2025 Business Results
Medium
Report
AbCellera Reports Q3 2025 Business Results
10/21
10:55 pm
abcl
AbCellera Biologics Inc. (ABCL): A Bull Case Theory [Yahoo! Finance]
Low
Report
AbCellera Biologics Inc. (ABCL): A Bull Case Theory [Yahoo! Finance]